What are your thoughts on the relevance of sentinel lymph node biopsy before the onset of neoadjuvant chemotherapy for HER2+ or triple negative cT2+N0M0 breast cancer patients?
1 Answers
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network
We don’t favor SNLN bx upfront as systemic agent is the same for the two phenotypes for T2 and the above disease and will tailor the RT field based on the final pathology.
